A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19

11/6 Pre-Exposure Prophylaxis study (treated before exposed to the virus)

Zhou et al., PLOS Biology, doi:10.1371/journal.pbio.3000970 (Peer Reviewed)
A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19

Source PDF Share Tweet

PSM observational study with a database of 26,779 patients in the USA, showing significantly lower risk of PCR+ with melatonin usage.

Zhou et al., 11/6/2020, retrospective, propensity score matching, USA, North America, peer-reviewed, 18 authors.

risk of COVID-19 case, 21.1% lower, RR 0.79, p < 0.001, treatment 222 of 1055 (21.0%), control 8052 of 25724 (31.3%), odds ratio converted to relative risk, PSM.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 9 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit